NITTO DENKO CORP / ADR/
No enriched coverage for $NDEKF in the last 7 days.
No SEC Form 4 filings for $NDEKF in the last 30 days.
See all $NDEKF insider activity →Hemogenyx Pharmaceuticals (HEMO) has partnered with Nitto Denko to study targeted LNP delivery of its FLT3-CAR mRNA to T cells, aiming for an off-the-shelf in vivo CAR-T treatment. This is an early-stage R&D effort to expand beyond its ongoing HG-CT-1 autologous program.
Hemogenyx Pharmaceuticals (HEMO) has partnered with Nitto Denko to study targeted LNP delivery of its FLT3-CAR mRNA to T cells, aiming for an off-the-shelf in vivo CAR-T treatment. This is an early-stage R&D effort to expand beyond its ongoing HG-CT-1 autologous program.
AlphAI scores every news story that mentions NDEKF with an AI model for sentiment and relevance, and aggregates insider trades from NITTO DENKO CORP / ADR/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Hemogenyx Pharmaceuticals (HEMO) has partnered with Nitto Denko to study targeted LNP delivery of its FLT3-CAR mRNA to T cells, aiming for an off-the-shelf in vivo CAR-T treatment. This is an early-stage R&D effort to expand beyond its ongoing HG-CT-1 autologous program.
1 min read
